Another important role in triggering resistance to endocrine therapies in BC has been played by growth factors and their receptor signaling pathways, being able to activate ERα in absence of ligand [33]., Recently, has been reported that alterations in chromatin remodeling processes promote resistance to endocrine therapy. Here, ESR1 is linked to breast cancer.